



EDCTP Stakeholder Meeting on Malaria

19-20 September 2013
 Austrian Ministry of Science and Research
 1st district of Vienna, Freyung 3, Vienna, Austria

Thursday 19 September 2013

08:30-09:30	Registration
08:30-09:30	Coffee/Tea
09:30-09:45	Opening addresses <ul style="list-style-type: none"> • Dr Christiane Druml, Vice-Rector of Clinical Issues, Medical University Vienna, Austria • Mag. Barbara Weitgruber, Director General for Research and International Relations of the Austrian Ministry of Science and Research, Austria • Prof. Charles Mgone, Executive Director EDCTP, The Netherlands
09:45-10:00	Introduction by Chairpersons Dr Salim Abdulla , Ifakara Health Institute, Tanzania Prof. Karen Barnes , University of Cape Town, South Africa
10:00-10:45	Plans and progress towards EDCTP2 Dr Michael Makanga , EDCTP, South Africa
10:45-11:20	Keynote address Prof. Abdoulaye Djimde , University of Science, Techniques and Technologies of Bamako, Mali <i>Recent research advances in malaria prevention and control</i>
11:20-11:30	Coffee/Tea
11:30-11:45	Antimalarials I: Global Drugs Portfolio Dr Tim Wells , Medicines for Malaria Venture, Switzerland
11:45-13:15	Discussion and recommendations
13:15-14:00	Lunch
14:00-14:45	Antimalarials II and Diagnostics Prof. Peter Kremsner , Tübingen University, Germany Prof. Jürgen May , Bernard-Nocht Institute, Germany <ul style="list-style-type: none"> • Severe malaria • Co-infections Prof. Clara Menendez , CRESIB, Spain <ul style="list-style-type: none"> • Pregnancy associated malaria • Intermittent preventive therapies Dr Mark Perkins , FIND, Switzerland <ul style="list-style-type: none"> • Diagnostics
14:45-15:30	Discussion and recommendations
15:30-15:45	Tea/Coffee
15:45-17:00	Antimalarials II and Diagnostics contd. Discussion and recommendations
17:00-17:15	Closing remarks, Day 1 <i>Chairpersons</i>
18:30	Dinner hosted by The Medical University of Vienna



Friday 20 September 2013

08:30-09:00	Registration
08:30-09:00	Coffee/Tea
09:00-09:10	Introduction by Chairpersons
09:10-09:25	Global Vaccine Portfolio Prof. Robert Sauerwein , Radboud University, The Netherlands
09:25-11:15	Discussion and recommendations
11:15-11:30	Coffee/tea
11:30-11:45	Malaria control Prof. Umberto D'Alessandro , MRC The Gambia
11:45-13:00	Discussion and recommendations
13:00-13:45	Lunch
13:45-15:45	<p>Partnerships</p> <p>Panel Discussion</p> <ul style="list-style-type: none"> • Prof. Francine Ntoumi, Congolese Foundation for Medical Research • Prof. Christian Burri, Swiss Tropical and Public Health Institute • Dr Ambrose Talisuna, Worldwide Antimalarial Resistance Network (WWARN) • Dr Val Snewin, Wellcome Trust • Dr Inma Jimenez, Directorate General of Research and Innovation European Commission (EC) • Dr Odile Leroy, European Vaccine Initiative (EVI) • Dr Janice Culpeper, Bill and Melinda Gates Foundation • Dr Esthel van Brackel, GlaxoSmithKline Biologicals
15:45-16:00	Coffee/Tea
16:00-17:00	Summary and recap of recommendations
17:00-17:15	Closing remarks



Speaker Biographies

Chairpersons

Professor Karen Barnes first joined the University of Cape Town as a senior lecturer in 1995, and progressed via *ad hominem* promotions to associate professor in 2004 and full professor in 2008. Her work in malaria started when she was appointed as a member of the South African National Malaria Advisory Group in 1996. She subsequently joined the Regional Malaria Control Commission, the ACT Consortium, Worldwide Antimalarial Resistance Network and has served on a number of World Health Organization committees that guide malaria treatment policy. She is passionate about ensuring that evidence-based policies are effectively implemented into public sector practice. Within the 200,000km₂ of the Lebombo Spatial Development Initiative (LSDI) areas in Mozambique, Swaziland and South Africa, she has worked with the malaria control programmes and the Medical Research Council to develop the tools and skills essential for the successful implementation and monitoring of their new malaria treatment policies. Her research interests are mainly the comprehensive evaluation of malaria treatment policy changes in Southern Africa and improving antimalarial treatment for vulnerable populations.

Dr Salim Abdulla is a clinical epidemiologist with over 15 years of experience in the conduct of Phase I to Phase IV clinical trials, mainly focused on malaria. He has worked on the large-scale evaluation of insecticide-treated bednets, antimalarial drug resistance, and artemisinin-based combination therapy. He is currently involved in the evaluation of new malaria vaccines for regulatory licensure. Dr Abdulla also has experience in the development and implementation of malaria surveillance systems and conduct of national surveys for malaria indicators and drug resistance. Since 2008, Dr Abdulla has served as the Chief Executive Director of Ifakara Health Institute (IHI), which now employs over 1,200 staff across 7 sites in Tanzania. Dr Abdulla has published extensively and serves on various national and international technical committees. He maintains a keen interest in translating research into policy and practice and has played an important role in the formulation of national policy on ITNs and malaria treatment.

Plenary Speaker

Professor Abdoulaye Djimde received a PharmD in Bamako, Mali in 1988 and a PhD in Maryland, Baltimore, Maryland, USA in 2001. He is currently Head of the Molecular Epidemiology and Drug Resistance Unit of the Malaria Research and Training Center, University of Bamako. The primary goal of his research is to understand how the malaria parasite becomes resistant to antimalarial drugs and how that resistance spreads over time and space. With his team and collaborators he conducts field and laboratory based analyses to explore how genetic events in the malaria parasite, the human host and the mosquito vector's genomes relate to treatment outcome and the spread of drug resistance. He has co-authored over seventy five peer reviewed scientific publications. He sits on numerous Malian, African and International committees on Malaria and Health Research issues.

Session Speakers

Professor Dr. Peter Kremsner, has been director of the Institut für Tropenmedizin at the Eberhard Karls Universität Tübingen since November 2008, and since 2012 he is also the director of the Comprehensive Infectious Disease Center (CIDiC). After having been at the Institut für Spezifische Prophylaxe und Tropenmedizin der Universität Wien from 1983 to 1987, Professor Kremsner joined the Institut für Tropenmedizin in Berlin. In 1996 he was appointed to a professorship at the Institut für Tropenmedizin in Tübingen. Since 1992 Professor Kremsner has been the head of the Centre de Recherches Médicales de Lambaréné and Scientific Director of the Albert Schweitzer Hospital in Gabon. He has published more than 400 scientific papers with an h-index of 54.



Dr Tim Wells joined the Medicines for Malaria Venture (MMV) in 2007 as Chief Scientific Officer and has responsibility for the Research and Development Portfolio, which covers over 50 projects from screening, through to one launched product and two products currently preparing for registration. Prior to joining MMV, he was Senior Executive Vice President Research at Serono. Prior to this he worked at the Glaxo Institute for Molecular Biology. He was awarded a ScD in Biology from the University of Cambridge for his later work on Cytokine Biology and has a PhD in Chemistry from Imperial College, London for Protein Engineering studies on enzyme catalysis, with Sir Alan Fersht. He is a Fellow of the Royal Society of Chemistry and the UK Academy of Medical Sciences. He has over 180 scientific publications, and several patent applications.

Dr Clara Menéndez is a Research Professor at the Barcelona Centre for International Health Research (CRESIB) and ISGlobal, where she directs the Maternal, Infant and Reproductive Health Initiative. Currently, most of her research is carried out at the Manhica Health Research Centre (CISM) in Mozambique. The Maternal, Infant and Reproductive Health Initiative led by Dr Menéndez at ISGlobal aims to contribute to improving the health of women and children in developing countries through a multidisciplinary approach involving research, training, advocacy and cooperation. Dr Menéndez is a lecturer at the Master of Global Health at the Universitat de Barcelona, the Master of Public Health at the Universitat Pompeu Fabra and at the Diploma of International Tropical Pediatrics at the Instituto de Salud Carlos III. She is also a consultant for the World Health Organization on malaria control in children and pregnant women. She has supervised 17 doctoral theses and published more than one-hundred articles in peer reviewed scientific journals. She was awarded the Rudolf Geigy Award in 2006, from the Swiss Tropical Institute for international research commitment. She was also awarded the Príncipe de Asturias Award for International Cooperation in 2008. In 2012, Dr Menendez was awarded the Women's Health award of the Dexeus Foundation.

Dr Mark Perkins trained in Internal Medicine and Pediatrics at Vanderbilt in Nashville, Tennessee, and was chief resident in Pediatrics. Dr Perkins is Board Certified in Internal Medicine, Pediatrics, Infectious Diseases, Clinical Microbiology, and Tropical Medicine. In 1998 he joined the Global Tuberculosis Programme of the World Health Organization and the following year established a Diagnostics unit in the Special Programme for Research and Training in Infectious Diseases (TDR). Funding from the Gates Foundation in 2001 allowed the creation of a full program on TB diagnostics within TDR. Subsequent grant funding from the Gates Foundation in 2003 established the Foundation for Innovative New Diagnostics to accelerate this work.

Professor Robert Sauerwein has been a malaria researcher for over 25 years with special interest in clinical malaria vaccine and drug development. His compendium includes more than 260 peer reviewed papers. He is the leader of the Medical Parasitology group of the Department of Medical Microbiology at Radboud University Nijmegen Medical Centre, consisting of 25 international investigators. His laboratory has been engaged in gaining an understanding of the mechanisms of *P falciparum* development of gametocytes/ gametes and sporogony.

Professor Umberto D'Alessandro (MD, MSc, PhD) has been seconded in January 2011 from the Institute of Tropical Medicine in Antwerp, Belgium, to the Medical Research Council Unit in The Gambia as Theme Leader Disease Control & Elimination. He has substantial work experience in Africa, first as a clinician and later as a clinical epidemiologist. He has been involved in malaria research since 1990. He joined the Institute of Tropical Medicine in Antwerp in 1996, where he set up and led the Epidemiology Unit. There, he developed a research program around three themes: antimalarial treatment, including drug resistance, malaria prevention, and the *P. vivax* in vitro cycle. He is the coordinating investigator of the multicentre trial "Safe and efficacious artemisinin-based combination treatments for African pregnant women with malaria" funded by the EDCTP and the Gates Foundation.



Dr Michael Makanga is a medical doctor with Masters and PhD in Clinical Pharmacology and Therapeutics. He has considerable international experience in conducting and management of health research programmes with emphasis on the conduct of clinical trials, as well as ethics and clinical regulatory affairs. As EDCTP Director of South-South Cooperation and Head of Africa Office, he is responsible for liaison with the African political leadership, policy makers and the scientific community with the purpose of ensuring a genuine African ownership, commitment and stewardship of the partnership.

Partnership Panel Members

Professor Francine Ntoumi is currently Chair and Executive Director of the Congolese Foundation for Medical Research, and Project Coordinator of CANTAM. She was the Multilateral Initiative on Malaria (MIM) Coordinator until August 2010. In this role one of her main aims was to build a pool of African malaria researchers, particularly encouraging more women into science. Prior to 2007, she was Senior Scientific Officer at EDCTP. In 2010 *Le Metropolis* magazine made her one of Congo's top 50 women to make their mark on the country's history.

Professor Christian Burri, is the Head of the Department of Medicines Research at the Swiss Tropical & Public Health Institute (Swiss TPH) and Professor for pharmacy & clinical pharmacology at the Department of Pharmaceutical Sciences, University of Basel. From 2000 to 2011 he directed the Institute's academic CRO (PMU) specialized in the management of clinical trials on drugs and vaccines against tropical and poverty related diseases. He was also a member of the EDCTP Partnership Board from 2007-2011. Since 2011 he has been responsible for the Department's Research Cluster, which is active in translational research projects in drug development, epidemiology and public health, and in clinical trial methodology. Prof Burri has been trained as a pharmacist at the University of Bern, holds a PhD in medical parasitology from the University of Basel and he received post-doctoral training in molecular pharmacology at the Johns Hopkins University, Baltimore.

Professor Ambrose Talisuna completed his medical degree at Makerere University in 1992 and his Masters in Epidemiology from the London School of Hygiene and Tropical Medicine in 1996. He was awarded a PhD from the University of Antwerp and Institute of Tropical Medicine for his work on intensity of transmission and spread of antimalarial drug resistance in 2004. Between 1996 and 2011 Ambrose held senior positions within the Ugandan Ministry of Health, the Medicines for Malaria Venture (MMV) and was the field coordinator for the multi-country malaria clinical trial supported by EDCTP. He received a senior fellowship in 2007 from EDCTP to conduct a capacity strengthening project for pharmacovigilance of antimalarial drugs in Africa.

Dr Val Snewin is International Activities Manager at the Wellcome Trust following ten years of research into malaria at the Pasteur Institute, Paris, and as a research lecturer at Imperial College London, working on tuberculosis. Dr Snewin has a PhD in molecular mechanisms of malaria drug resistance and a post-doc in *P. vivax* transmission blocking. She has been working at the Wellcome Trust since 2000, including a secondment to the UK Department for International Development research team in 2005. Val works on the capacity development programmes of the Trust, mostly in Africa.



Mrs Inmaculada Peñas Jiménez has been working in the Infectious Diseases and Public Health Unit of the Directorate General of Research and Innovation of the European Commission since 2010 as malaria scientific officer. Trained in veterinary sciences in the University Complutense of Madrid, she joined the European Commission shortly after Spain became a Member State. From 1994-2005 she worked in the Marie Curie Fellowships unit as scientific officer for the life sciences panel managing the evaluation and follow up of the life sciences projects and contributing to the development of the researchers' careers and to remove obstacles to the mobility of researchers. From 2006-2009 she worked in settling the European Research Council executive agency. At present (2013) her portfolio is being extended to vector borne infectious diseases (dengue, tick borne diseases) and rabies.

Dr Odile Leroy has been the Executive Director of the European Vaccine Initiative since 2006 and has spent most of her career in vaccine development, as a scientist in Africa for nine years, followed by Corporate Clinical Director of airborne vaccines for ten years at Pasteur Mérieux Connaught (Sanofi Pasteur). She joined EVI in 2002 as Clinical and Regulatory Director, and from 2005 to 2006, she headed EDCTP as Executive Director. She is a member of the Science Board of the Brighton Collaboration, coordinator of the FP7 vaccine infrastructure project TRANSVAC, and a member of the WHO product development group for the measles aerosol project. Dr Leroy is a trained physician who has specialised in the areas of epidemiology, clinical pharmacology, and vaccinology.

Dr Janice Culpepper is a Senior Program Officer in Global Health at the Bill & Melinda Gates Foundation. She primarily focuses on investments for the development of drug and diagnostic for malaria; in her portfolio are grants to the Medicines for Malaria Ventures, PATH, and the Innovative Vector Control Consortium, as well as a number of grants to academic and research institutes. She had more than 20 years of experience in the biotechnology industry before joining the foundation in 2007. Dr Culpepper completed post-doctoral fellowships at UCSF and at the DNAX Research Institute in the US. She received her PhD in Biological Chemistry from Harvard University and her Bachelor's degree in Biology from Clark University.

Dr Esthel van Brackel is the VP Government Affairs & Public Policy Vaccines Developing World at GlaxoSmithKline Biologicals. She has over 30 years' experience in the pharmaceutical industry, seven years of which were spent working at GlaxoSmithKline Vaccines in the late-stage development of paediatric vaccines. In the past three years she has focused on public affairs, mainly in the areas of malaria, tuberculosis and dengue fever.